RLB MD PC

1. Sanofi US Services Inc. $699,332 95 payments
2. AbbVie, Inc. $639,668 117 payments
3. Janssen Research & Development, LLC $534,544 69 payments
4. Pfizer Inc. $256,271 19 payments
5. AstraZeneca Pharmaceuticals LP $195,396 28 payments
6. GlaxoSmithKline, LLC. $90,028 36 payments
7. E.R. Squibb & Sons, L.L.C. $53,817 2 payments
8. Genzyme Corporation $51,464 18 payments
9. Chiesi USA, Inc. $31,623 12 payments
10. Esperion Therapeutics, Inc. $28,683 49 payments

1. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $243,628 19 payments
2. A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain $210,462 1 payment
3. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $200,270 23 payments
4. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis $192,768 14 payments
5. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $143,657 9 payments
6. M15-997 $138,431 28 payments
7. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment $138,165 25 payments
8. A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata $119,914 19 payments
9. A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $109,540 16 payments
10. M16-813 $73,031 18 payments

1. Other $2,365 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.